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Abstract
Purpose In patients with localised neuroblastoma without
adverse genetic aberrations, observational treatment is justi-
fied. Therapy is required when organ or respiratory func-
tions have become compromised. As the outcome is good,
side effects of treatment should be prevented. The aim of
this retrospective study was to evaluate response and out-
come in patients treated with 131I-metaiodobenzylguanidine
(MIBG) for unresectable localised neuroblastoma, with
compromised organ functions.
Methods Patients with localised neuroblastoma [median age
1.6 years (0–5.5 years)] diagnosed between 1989 and 2008
were included in this retrospective study (n=21). Primary
tumours were unresectable and there was a compromised
organ or respiratory function. Diagnosis and staging were
performed according to the International Neuroblastoma
Staging System. Fixed doses of 131I-MIBG therapy (50–
200 mCi) were given. The median number of infusions
was two (range one to seven). Response was graded
according to the International Neuroblastoma Response
Criteria.
Results Of the 21 patients, 14 did not need any chemother-
apy. Patients were treated with 131I-MIBG therapy and, in
most cases, with additional surgery and/or chemotherapy.
Sixteen achieved complete response (CR), three very good
partial response (VGPR), one partial response (PR) and one
progressive disease (PD). Two patients died of PD after
having achieved CR initially and due to surgical complica-
tions a few months after resection. Ten-year overall survival
and event-free survival were 90.5 %. The median follow-up
was 8.5 years (range 0.4–19.6 years).
Conclusion 131I-MIBG therapy is an effective treatment
modality for unresectable localised neuroblastoma with
compromised organ functions. However, this was a small
and heterogeneous cohort and further studies are needed.
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Introduction
Neuroblastoma is the most common extracranial solid tu-
mour of childhood. Arising from the neural crest, primary
tumours can be localised in the adrenal glands or anywhere
along the sympathetic side chain. Important prognostic fac-
tors are age, stage, MYCN amplification (MNA), loss of
heterozygosity of chromosome 1p (1pLOH), chromosomal
11q aberration and DNA ploidy [1]. Approximately 25 % of
patients present with localised disease without distant
metastases.
Treatment modality and intensity of treatment in patients
with localised disease, stage 1–3 [International Neuroblastoma
Staging System (INSS)], are based upon risk stratification and
defined by age, stage and biological features. The
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prognosis is good and the majority of patients can be
cured by surgery alone or by a combination of surgery
and chemotherapy [2].
If the primary tumour causes or is in danger of causing
organ or respiratory dysfunction, as in paravertebral tu-
mours with spinal cord compression, (urgent) treatment is
needed. In these circumstances, volume reduction is neces-
sary to reduce symptoms, usually with (neuro-) surgical
resection (i.e. laminectomy). In these patients, treatment
with chemotherapy is often recommended [3]. However, as
the prognosis of localised neuroblastoma is good, toxicity
and late effects should be minimised. Targeted radiotherapy
with 131I-metaiodobenzylguanidine (MIBG) is an effective
treatment modality for neuroblastoma and rarely causes
severe toxicity [4, 5].
The use of 131I-MIBG as initial therapy in patients
with localised neuroblastoma has not been reported thus
far. The aim of this retrospective study was to investigate
the effect of 131I-MIBG therapy on resectability and
outcome in patients with unresectable localised neuro-




In this retrospective cohort study we included all (21)
neuroblastoma patients (0–18 years) diagnosed with INSS
stage 1–3, treated initially with 131I-MIBG therapy, with
inoperable MIBG-positive lesions that were causing or
were in danger of causing organ dysfunction. The study
was performed in the Emma Children’s Hospital/Academic
Medical Centre (EKZ/AMC) in Amsterdam between 1989
and 2008. Patients were treated with 131I-MIBG therapy if
volume reduction was necessary to reduce symptoms of
compromised organ or respiratory function and if tumour
resection was not possible. Nine patients have been de-
scribed before [6].
Staging
The diagnostic workup consisted of imaging, analysis of
urinary catecholamines, bone marrow biopsies/trephines,
serum lactate dehydrogenase (LDH) and ferritin. Extension
of the tumour was visualised with ultrasound (US), 123I-
MIBG scintigraphy, computed tomography (CT) and/or
magnetic resonance imaging (MRI). The diagnosis was
confirmed histologically, with tissue obtained either by
fine-needle aspiration, Tru-Cut biopsy or excisional bi-
opsy. Staging was performed according to the INSS
criteria [7].
Treatment
Patients were treated with 131I-MIBG according to the proto-
col previously described by de Kraker et al. [4]. Fixed doses
were given; the first dose was either 200 or 150 mCi (7,400 or
5,550 MBq), and the second dose was lower, 150 or 100 mCi
(5,550 or 3,700 MBq). Doses were adjusted based on age and
stage. 131I-MIBG was infused slowly (100 mCi/h) with an
interval of 4 weeks. Patients remained in radioprotective iso-
lation until the exposure rate was less than 20 μSv/h, mea-
sured with a counter at a distance of 1 m from the patient [4].
The parents were extensively informed about the nature
and precise elements of the treatment and the differences from
other strategies and consent was obtained prior to treatment.
Response
Response was graded according to the International Neuro-
blastoma Response Criteria (INRC) [7]. Response of the
tumour was evaluated 3–4 weeks after each course.
Patients underwent multiple 131I-MIBG therapies if treat-
ment was tolerated well, if 131I-MIBG uptake in the tumour
was sufficient and if response was ongoing, but the tumour
remained unresectable. Gross total resection was defined as
removal of more than 95 % of the tumour. Partial resection
was defined by the presence of macroscopic remnants.
Overall survival (OS) was measured as the time from
start of treatment to death by any cause. Event-free survival
(EFS) was defined as the time from start of treatment to a
first event (progression, relapse or death).
Statistical analysis
OS and EFS were estimated by the Kaplan-Meier method.
Patients were censored in the EFS analysis if they were lost




Between 1989 and 2008, 21 patients (8 male, 13 female)
with localised neuroblastoma (INSS stage 1–3) were treated
with 131I-MIBG in the EKZ/AMC. The median age at diag-
nosis was 1.6 years (range 0–5.5 years); nine patients (43 %)
were 1 year or younger (Table 1, Supplementary Table 1).
According to the INSS staging criteria, four neuroblastomas
were classified as stage 1, three as stage 2 and 14 as stage 3.
Tumours were localised in the abdomen in 11 patients.
Other localisations were thoracic (n=5), pelvic (n=4) and
the neck (n=1).
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Seventeen patients had a neuroblastoma and four a
ganglioneuroblastoma. Genetic aberrations were analysed
in 18 patients: MNA was present in two tumours, 1pLOH
in one and both aberrations in another patient. Urinary
catecholamines were elevated in 18 patients; 3 patients with
ganglioneuroblastoma had normal excretion (stage 1). LDH
levels were elevated in 6 patients; ferritin was elevated in 4
of 18 patients.
131I-MIBG therapy
Primary resection of the tumour was not feasible in all
patients and the tumour caused or was in danger of causing
organ or respiratory dysfunction (Table 2, Supplementary
Table 2). Tumour extension into the spinal canal was the
indication for 131I-MIBG therapy in seven patients. This
caused neurological deficits in six patients. Indications for
131I-MIBG therapy in the remaining 14 patients were: com-
pression of the trachea, close relationship to the kidney,
encasement of major vessels, attachment to the crus of the
diaphragm, partial intestinal obstruction or hydronephrosis.
The median number of 131I-MIBG therapies given was two
(range one to seven). Administered doses varied from 5.8 to
20.6 mCi/kg (median 13.4 mCi/kg) during the first treatment
and from 5.9 to 16.3 mCi/kg (median 12.4 mCi/kg) during the
second treatment. 131I-MIBG therapy was combined with
topotecan in two patients according to the protocol that was
used during that period.
Response
Delivered therapy and response are presented in Fig. 1.
Treatment with solely 131I-MIBG therapy without additional
chemotherapy (group A) in two patients resulted in






Age at diagnosis (years)
Median (range) 1.6 (0–5.5)






















0–1 year (≥400 U/l) 3/9
1–17 years (≥300 U/l) 3/12
Ferritin
≥143 ng/ml 4/18
n number of patients, INSS International Neuroblastoma Staging
System, MNA MYCN amplification, 1pLOH chromosome 1p loss of
heterozygosity, LDH lactate dehydrogenase
Table 2 131I-MIBG therapy characteristics
Number (%)
n 21
Reasons for 131I-MIBG therapy










First 131I-MIBG-dose in mCi (Mbq)
50 (≈1,850) 2 (10)
100 (≈3,700) 4 (19)
150 (≈5,550) 7 (33)
200 (≈7,400) 6 (28)
Unknown 2 (10)
Second 131I-MIBG-dose in mCi (Mbq)
50 (≈1,850) 1 (5)
100 (≈3,700) 7 (39)
150 (≈5,550) 7 (39)
200 (≈7,400) 0
Unknown 3 (17)
n number of patients, MIBG metaiodobenzylguanidine, mCi millicurie,
MBq megabecquerel
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complete response (CR) in one patient and a very good
partial response (VGPR) in the other. This last patient was
considered inoperable after 131I-MIBG therapy as the resid-
ual tumour was located against the crus of the diaphragm.
CR was achieved in seven patients after 131I-MIBG therapy
followed by surgery (group B). 131I-MIBG therapy, surgery
and chemotherapy (group C) were given in three patients.
One of them received two cycles of vincristine, etoposide,
carboplatin and ifosfamide (VECI) after surgery because of
1pLOH and achieved CR. 1pLOH was not yet incorporated
in the neuroblastoma risk stratification at that time, but
increased risk was suspected based on preliminary data. In
a second patient high-risk (HR) neuroblastoma (MNA and
1pLOH) was diagnosed and treated according to the HR
protocol following 131I-MIBG therapy; subsequently CR
was achieved. The third patient was treated with one VECI
cycle while waiting for 131I-MIBG therapy; after 131I-MIBG
therapy disease progressed and HR treatment was initiated.
This patient died of progressive disease (PD).
Nine patients had treatment prior to 131I-MIBG thera-
pies. Surgery was the treatment preceding 131I-MIBG
therapy (group D) in five patients. A laminotomy was
performed in one patient because of tumour progression;
this patient continued with 131I-MIBG therapy and
achieved CR. Another patient underwent a laminectomy
to relieve symptoms caused by an intraspinal tumour.
The tumour recurred 4 months later and the patient was
re-operated. A second relapse was treated with two cy-
cles of 131I-MIBG therapy and CR was achieved. An
emergency laminectomy and laminotomy were necessary in
a third patient because of intraspinal extension of the tumour
and this patient achieved CR after 131I-MIBG therapies. A
presacral tumour in a fourth patient was treated with 131I-
MIBG therapy after incomplete surgery. This patient achieved
partial response (PR) after five cycles of 131I-MIBG therapy
and the residual lesion remained stable during follow-up. The
fifth patient was an infant at diagnosis and had a partial
resection of a retroperitoneal presacral tumour in order to
delay 131I-MIBG therapy. This patient achieved CR after
131I-MIBG therapy.
Both chemotherapy and surgery preceding 131I-MIBG
therapy (group E) were applied in two patients. A
laminotomy followed by a laminectomy and chemother-
apy (CADO: cyclophosphamide, vincristine and doxoru-
bicin) were performed in one patient. Because of PD
during chemotherapy this patient received two cycles of
131I-MIBG therapy and subsequently achieved VGPR
with a residual primary lesion that remained stable dur-
ing follow-up. The other patient was treated with two
cycles of vindesine, VP-16 and cisplatin followed by
decompressive surgery in her home country preceding
131I-MIBG therapy achieving VGPR. Four months after
the third course of 131I-MIBG therapy, she underwent a
(macroscopic complete) surgical resection in the home
country, despite the presence of surgical risk factors. As
a complication of surgery, she became tetraplegic and
died a few months later of an infection.
Modified cycles of chemotherapy were started before
131I-MIBG therapy (group F) in two patients. The first
patient was treated in the home country with CADO before
coming to our centre. The second patient was suspected to
have a Wilms’ tumour and was pretreated with vincristine
and actinomycin; both achieved CR. No toxic deaths related
to 131I-MIBG therapy occurred.
In conclusion, 16 of 21 patients achieved CR after treat-
ment. Residual but stable disease (three VGPR, one PR) was
achieved in four patients. One patient had PD and conse-















B. 131I-MIBG+surgery: n=7 7
Fig. 1 Flow chart response. MIBG metaiodobenzylguanidine, chemo chemotherapy, CR complete response, VGPR very good partial response, PR
partial response, MR mixed response, NR no response, PD progressive disease
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(Fig. 2). The median follow-up was 8.5 years (range 0.4–
19.6 years).
Discussion
We conclude that 131I-MIBG therapy is an effective
treatment modality for unresectable localised neuroblas-
toma causing or in danger of causing organ or respiratory
dysfunction. Of the 21 patients, 14 did not need
chemotherapy.
In patients with localised neuroblastoma, without MNA or
1pLOH, observation or surgery is usually recommended [8].
Since the start of 131I-MIBG therapy in the 1980s, several
reports have described its efficacy and toxicity proven to be
mild and infrequent [4]. Phase I/II studies in patients with
refractory or relapsed neuroblastoma showed a response rate
of 10–56 %. Persistent thrombocytopenia was the main
Overall Survivala
b Event Free Survival
Fig. 2 a OS: 10-year OS=
90.5 %, median follow-up=
8.5 years (range 0.4–
19.6 years). Time since
diagnosis: years. b EFS:
10-year EFS=90.5 %, median
follow-up=8.5 years (range
0.4–19.6 years). Time since
diagnosis: years
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toxicity observed in these extensively pretreated patients [9].
Because 131I-MIBG therapy was effective with limited toxic-
ity, the patients with localised neuroblastoma in our cohort
were treated with 131I-MIBG therapy, rather than chemother-
apy when urgent treatment was indicated.
In this report, 131I-MIBG therapy proved to be a good
alternative for chemotherapy for at least 14 of 21 (66.7 %)
patients. Tumours regressed completely; residual lesions
became resectable or remained stable. One exception was
a HR tumour with MNA and 1pLOH that progressed during
HR treatment and the patient eventually died.
The 10-year OS was 90.5 %. However, compared to
other cohorts treated with chemotherapy and/or surgery,
our cohort is small and heterogeneous. It included infants
as well as older children with different risk profiles and
different pre- and post-treatment modalities.
Since the prognosis of localised neuroblastoma is good,
toxicity and late effects should be avoided if possible. Hence,
Rubie et al. reported a 5-year OS of 99 % for a heterogeneous
patient group of 120 infants. This group consisted of patients
with and without threatening symptoms and different treatment
strategies. The study stated that low-dose chemotherapy with-
out anthracyclines was effective in 62 % of infants with an
unresectable neuroblastoma and no MNA [3]. No treatment-
related deaths were observed. However, PD and recurrence
occurred in 12 of 120 patients. Two patients in our cohort died.
These deaths were not related to 131I-MIBG therapy but to
progressive HR disease and to complications of surgery.
131I-MIBG therapy is mainly reported in patients with
refractory or relapsed neuroblastoma. These patients have
been treated with multiple preceding treatment modalities
and therefore it is difficult to report which late effects are
caused by 131I-MIBG therapy alone.
Thyroid toxicity is a known side effect of 131I-MIBG
therapy. Although thyroid protection during 131I-MIBG ther-
apy mostly prevents 131I thyroid uptake, late effects of 131I-
MIBG therapy on thyroid function cannot be ruled out.
Recently, our group reported two patients with differentiated
thyroid carcinoma following 131I-MIBG therapy [10]. These
patients received adequate thyroid protection during 131I-
MIBG therapy, and no 131I-MIBG uptake was seen in their
thyroids on MIBG imaging. So, although no clear evidence is
available thus far, patients should be checked regularly for
thyroid problems after 131I-MIBG therapy. None of the pa-
tients described in this report developed a thyroid carcinoma.
In current protocols genetic aberrations such as MNA,
1pLOH and 11q aberration are included in risk classification
systems [1]. Three patients from our cohort were treated before
genetic aberrations were implemented in treatment protocols.
MNA and 1pLOH were present in one patient with a stage 3
neuroblastoma. This patient was eventually treated as a HR
patient after three courses of 131I-MIBG therapy and is still alive
11 years after treatment. MNAwas present in two other patients
(stage 2 and 3). These two patients received two courses of 131I-
MIBG therapy followed by a complete resection and are still
alive after 12.2 and 7.5 years of follow-up respectively.
We conclude that 131I-MIBG therapy is an effective treat-
ment modality for unresectable localised neuroblastoma
causing or in danger of causing organ or respiratory dys-
function and offers a good alternative to chemotherapy if
urgent treatment is needed. However, for the assessment of
long-term toxicity, long-term follow-up for all patients treat-
ed with chemotherapy and/or with 131I-MIBG is needed.
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